Tirzepatide NEW

$0.00 1box

$0.00 10box

$0.00 100box

Min. Order1box
Purity99.99%
Cas No2023788-19-2
Supply Ability10000
Update time2026-04-03

Shandong Huizhihan Supply Chain Co., Ltd

VIP2Y

China

Chemical Properties

Product Name	Tirzepatide
CAS No	2023788-19-2
EC-No
Min. Order	1box
Purity	99.99%
Supply Ability	10000
Release date	2026/04/03

factory directly supply semaglutide 910463-68-2 Tirzepatide 2023788-19-2 Retatrutide 2381089-83-2 MotsC ,Nad+,Kpv, Reta 15,Tesa/ipa 4 kits or tesa 4 and ipa 4,Bpc,Tb500,Ghkcu,Ss31,Slupp332,Cagriwith fast delivery 4-7 days to USA Canada UK Australia

Product Description

Research Peptide Semaglutide Tirzepatide Retatrutide... etc API

Items Name	Tirzepatide API (Research Purpose Only)	Costomize	2mg 5mg 10mg 15mg 20mg 30mg 60mg
CAS Code	2023788-19-2	Vial size	3ml/5ml/10ml
Raw Materials	White Powder	Type	Lyophilized process, vaccum seal
Package	White Paper Box	GMP	Fully GMP standard operation
Test Method	HPLC, MS	Filling Vial	over filled each vial
Cap color	Multiple colors customize	Payment Way	SWIFT, ACH, Fedwire, Bank Wire, Wise, Revolut,
Purity Content	99-100%	Reship Policy	Yes

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclinical and clinical trials. Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety.

Its protein sequence was based on the sequence of endogenous GIP, and its pharmacological action on GLP-1 receptors is comparable to endogenous GIP; however, the long half-life of tirzepatide allows for once-weekly dosing. Tirzepatide was approved by the F/DA on May 13, 2022, under the brand name MO/UNJ/ARO by the FDA for the treatment of adults with type 2 diabetes, making it the first and only GIP and GLP-1 receptor agonist for this indication. Later, it was approved under a different brand name ZEP/BO/UND on November 8, 2023, for the chronic weight management in adults with obesity or overweight with at least one weight-related condition. On September 15, 2022, tirzepatide was also approved by the European Commission.